Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Alterity Therapeutics Ltd. ( (AU:ATH) ) has shared an announcement.
Alterity Therapeutics announced promising results from its Phase 2 trial of ATH434 for early-stage multiple system atrophy (MSA). The trial demonstrated a significant slowing of clinical progression, with up to 48% reduction on a key disability scale, and showed favorable safety outcomes. The results, which include evidence of iron stabilization in affected brain regions, suggest ATH434’s potential to be a pioneering treatment for MSA, a disease currently lacking approved therapies. Alterity intends to engage with the FDA to discuss accelerating development, given the unmet medical need.
More about Alterity Therapeutics Ltd.
Alterity Therapeutics is a biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases. Their primary market focus is on providing therapies for conditions such as multiple system atrophy, Friedreich’s ataxia, and major disorders like Parkinson’s and Alzheimer’s diseases.
YTD Price Performance: 0%
Average Trading Volume: 100
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $26.53M
See more insights into ATH stock on TipRanks’ Stock Analysis page.
